3 research outputs found
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Background: Based on the encouraging activity and manageable safety profile observed in a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of CD30-positive peripheral T-cell lymphomas. Methods: ECHELON-2 is a double-blind, double-dummy, randomised, placebo-controlled, active-comparator phase 3 study. Eligible adults from 132 sites in 17 countries with previously untreated CD30-positive peripheral T-cell lymphomas (targeting 75% with systemic anaplastic large cell lymphoma) were randomly assigned 1:1 to receive either A+CHP or CHOP for six or eight 21-day cycles. Randomisation was stratified by histological subtype according to local pathology assessment and by international prognostic index score. All patients received cyclophosphamide 750 mg/m2 and doxorubicin 50 mg/m2 on day 1 of each cycle intravenously and prednisone 100 mg once daily on days 1 to 5 of each cycle orally, followed by either brentuximab vedotin 1·8 mg/kg and a placebo form of vincristine intravenously (A+CHP group) or vincristine 1·4 mg/m2 and a placebo form of brentuximab vedotin intravenously (CHOP group) on day 1 of each cycle. The primary endpoint, progression-free survival according to blinded independent central review, was analysed by intent-to-treat. This trial is registered with ClinicalTrials.gov, number NCT01777152. Findings: Between Jan 24, 2013, and Nov 7, 2016, 601 patients assessed for eligibility, of whom 452 patients were enrolled and 226 were randomly assigned to both the A+CHP group and the CHOP group. Median progression-free survival was 48·2 months (95% CI 35·2–not evaluable) in the A+CHP group and 20·8 months (12·7–47·6) in the CHOP group (hazard ratio 0·71 [95% CI 0·54–0·93], p=0·0110). Adverse events, including incidence and severity of febrile neutropenia (41 [18%] patients in the A+CHP group and 33 [15%] in the CHOP group) and peripheral neuropathy (117 [52%] in the A+CHP group and 124 [55%] in the CHOP group), were similar between groups. Fatal adverse events occurred in seven (3%) patients in the A+CHP group and nine (4%) in the CHOP group. Interpretation: Front-line treatment with A+CHP is superior to CHOP for patients with CD30-positive peripheral T-cell lymphomas as shown by a significant improvement in progression-free survival and overall survival with a manageable safety profile. Funding: Seattle Genetics Inc, Millennium Pharmaceuticals Inc, a wholly owned subsidiary of Takeda Pharmacuetical Company Limited, and National Institutes of Health National Cancer Institute Cancer Center
The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers - two independent studies
The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers--two independent studies.
BACKGROUND: The WHO scheme for prothrombin time (PT) standardization has been
limited in application, because of its difficulties in implementation,
particularly the need for mandatory manual PT testing and for local provision of
thromboplastin international reference preparations (IRP).
METHODS: The value of a new simpler procedure to derive international normalized
ratio (INR), the PT/INR Line, based on only five European Concerted Action on
Anticoagulation (ECAA) calibrant plasmas certified by experienced centres has
been assessed in two independent exercises using a range of commercial
thromboplastins and coagulometers. INRs were compared with manual certified
values with thromboplastin IRP from expert centres and in the second study also
with INRs from local ISI calibrations.
RESULTS: In the first study with the PT/INR Line, 8.7% deviation from certified
INRs was reduced to 1.1% with human reagents, and from 7.0% to 2.6% with rabbit
reagents. In the second study, deviation was reduced from 11.2% to 0.4% with
human reagents by both local ISI calibration and the PT/INR Line. With rabbit
reagents, 10.4% deviation was reduced to 1.1% with both procedures; 4.9%
deviation was reduced to 0.5% with bovine/combined reagents with local ISI
calibrations and to 2.9% with the PT/INR Line. Mean INR dispersion was reduced
with all thromboplastins and automated systems using the PT/INR Line.
CONCLUSIONS: The procedure using the PT/INR Line provides reliable INR derivation
without the need for WHO ISI calibration across the range of locally used
commercial thromboplastins and automated PT systems included in two independent
international studies